Status:
COMPLETED
Abilify Therapy for Reducing Comorbid Substance Abuse
Lead Sponsor:
Creighton University
Collaborating Sponsors:
Bristol-Myers Squibb
Conditions:
Schizophrenia
Schizoaffective Disorder
Eligibility:
All Genders
19-65 years
Phase:
PHASE4
Brief Summary
It is hypothesized that the use of aripiprazole (Abilify) in patients with alcohol and/or drug dependence with comorbid psychiatric conditions will lead to: * Reduction in the amount of alcohol and/o...
Detailed Description
Substance abuse disorders are a major public health problem. With a current prevalence rate of 18%, substance abuse and dependence costs the nation over $300 billion per year in treatment costs and lo...
Eligibility Criteria
Inclusion
- Ages 19 - 65
- Diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder, or anxiety (panic disorder, generalized anxiety disorder, or post-traumatic stress disorder) as confirmed by Mini International Neuropsychiatric Interview (MINI) structured assessment
- Diagnosis of comorbid substance abuse/dependence as confirmed by the MINI structured assessment
- Ability to provide signed informed consent
- Stable general medical health
- Ability to attend outpatient research clinic.
Exclusion
- Dangerous to self or others
- Pregnancy, or inability or unwillingness to use approved methods of birth control
- Inability or unwillingness to provide signed informed consent
- Inability to attend outpatient research clinic
- Medical conditions, which would preclude use of aripiprazole
- Absolute need for ongoing treatment with antipsychotic other than aripiprazole
- Medical instability defined as likelihood of needing to change prescription medication during the course of the study
- Patients with prior unsuccessful treatment with aripiprazole
- Patients with a psychiatric diagnosis of only antisocial personality disorder or only an eating disorder and comorbid substance abuse/dependence.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00208169
Start Date
March 1 2005
End Date
June 1 2007
Last Update
August 24 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Creighton University Psychiatry and Research Center
Omaha, Nebraska, United States, 68131